MediWound

Company snapshot

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a la

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MediWound. Not investment advice.

• What is MediWound?

  MediWound Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Venous leg ulcer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sourc

• Is MediWound publicly traded?

  MediWound appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does MediWound develop or market?

  We link 1 drug profile(s) where MediWound is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mediwound-germany-gmbh#company-drugs.

• What are the latest developments for MediWound?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MediWound focus on?

  MediWound focuses on Venous leg ulcer based on our analysis of their pipeline programs and drug development activities.